华特达因：近一年来公司子公司达因药业获得了丙戊酸钠口服溶液和盐酸可乐定缓释片的药品注册证书

Core Viewpoint - The company focuses on developing pediatric medications, emphasizing the need for tailored drug solutions for children and maintaining high-quality standards in design and production [2] Group 1: Product Development - The subsidiary, Dain Pharmaceutical, has received drug registration certificates for sodium valproate oral solution and sustained-release clonidine tablets [2] - The company has initiated clinical trials for the inhalation aerosol of ipratropium bromide, indicating a commitment to expanding its product pipeline [2] Group 2: Strategic Focus - The company aims to enhance its core competitiveness by continuously developing 1-2 new pediatric-specific medications each year [2] - The research and development efforts are directed towards addressing clinical needs in mental health, respiratory, and digestive fields, aligning with children's health and nutritional requirements [2]